Lacroix et al revealed that DDX3X was required for the lymphoid differentiation and MYC‐driven lymphomagenesis, which indicated that inhibiting the expression of the DDX3X gene could be a treatment strategy for the MYC‐driven B‐cell lymphoma.25 The gene discussed is DDX3X; the disease is B-cell non-Hodgkin lymphoma.